Re­gen­eron, mak­er of the block­buster oph­thal­mol­o­gy med­i­cine Eylea, has ac­quired an oc­u­lar biotech, the large bio­phar­ma con­firmed to End­points News on Thurs­day.

2024 was the year of the pri­vate megaround. Nine-fig­ure fi­nanc­ings dom­i­nat­ed biotech’s ven­ture fund­ing land­scape, with 96 such rounds tal­lied by End­points News. The bevy … ...

Carmell acquires Elevai Skincare, adding $2.5M in annual revenue and advanced exosome technology to its portfolio. Deal includes $1.1M in equity, $57K in cash, and earnouts tied to sales and ...

The biotechnology sector once again starts a new year on shaky footing. Acquisitions of publicly traded biotech companies have slowed. An anticipated upswing in initial public offerings hasn’t ...

Local biotech Heron Therapeutics is relocating its headquarters from San Diego to North Carolina, where it says the area’s burgeoning biotech scene “provides ample space for growth and ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins Some states have laws and ethical rules regarding solicitation and ...

Former Indian captain and veteran cricketer Vira Kohli has come in the firing line after his altercation with debutant Sam Konstas in Melbourne. Australian newspaper “The West Australian” had ...

While only around 330 Boston-area biotech employees were impacted by layoffs in the first quarter of 2024, that number rose to over 1,810 workers in the second quarter and more than 1,400 people ...

Lower interest rates boost biotech investments by increasing risk appetite, benefiting pre-commercial biotechs with high cash burn and no revenue. Biotech IPOs show resilience. Recent market ...

From the heart of the English commuter town, UK biotech Autolus will process, manufacture and ship to the US a new Car-T cell therapy to treat the blood cancer acute lymphoblastic leukaemia (ALL ...

We’ve sent a link to to change your password. Please check your inbox to reset your password securely and easily.

After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the ...